Investigational drug · Phase 2
BMS-986158
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelofibrosis, Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "BMS-986158"
First trial start
2021
Mar 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986158", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Myelofibrosis · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986158" as an intervention, largest first.
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05372354 · 260 participants (planned) · Start Oct 18, 2022 · Primary completion Oct 12, 2026
Drug: CC-92480; Tazemetostat and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Baltimore, Maryland; Boston, Massachusetts · 17 sites in all
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04817007 · 216 participants (planned) · Start Mar 22, 2021 · Primary completion Aug 31, 2028
Drug: BMS-986158; Ruxolitinib and 1 more · For: Myelofibrosis
Sites: Newport Beach, California; Lake Mary, Florida; New Orleans, Louisiana · 49 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02419417 · 83 participants · Start Jun 19, 2015 · Primary completion Mar 17, 2021
Drug: BMS-986158; Nivolumab · For: Advanced Tumors
Sites: Duarte, California; Aurora, Colorado; Boston, Massachusetts · 13 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03936465 · 41 participants · Start Sep 27, 2019 · Primary completion Mar 16, 2024
Drug: BMS-986158; BMS-986378 · For: Solid Tumor, Childhood; Lymphoma; Brain Tumor, Pediatric
Sites: Boston, Massachusetts; Ann Arbor, Michigan; Durham, North Carolina · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.
Tan S, Li Y, Cao Y, et al. · Ann Med 2026
- The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis.
Bellia M, Deambrogi C, Mahmoud AM, et al. · Expert Opin Investig Drugs 2026
- Ex Vivo Characterization Studies Identify Candidate Therapies for the Individualized Care of NF2-Related Schwannomatosis.
Hass EW, Nagel A, Scott AJ, et al. · Cancers (Basel) 2026
- Progress of investigational bromodomain and extra-terminal domain inhibitors for myelofibrosis therapy.
Beygui NC, Rogers M, Shah V, et al. · Expert Opin Investig Drugs 2026
- Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS).
Mondaza-Hernandez JL, Moura DS, Li Y, et al. · Neoplasia 2025
- Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death.
Cai C, Spinrad MW, Gattie LC, et al. · J Pharmacol Exp Ther 2025
Also in development for Myelofibrosis
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
- GB2064Phase 21 trial
Galecto Biotech AB · Myelofibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.